IP Library › Granted Patent US 8,486,695
Granted Patent B2
US 8,486,695 · App. 13/402,498 · Granted Jul 16, 2013

Mesenchymal stem cells expressing TNF-alpha receptors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,486,695
App. No.
13/402,498
Granted
Jul 16, 2013
Kind
B2
Abstract

Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 6 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.

Claims (9)

1. A method of obtaining mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 6 cells, comprising:

obtaining at least one cell population including mesenchymal stem cells from at least one donor;

determining the amount of TNF-α receptor Type I expressed by the mesenchymal stem cells in each of said at least one cell population; and

selecting mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 6 cells;

wherein said selected mesenchymal stem cells are non-transfected cells.

2. The method of claim 1 wherein said selected mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 15 pg/10 6 cells.

3. The method of claim 2 wherein said selected mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 18 pg/10 6 cells.

4. The method of claim 1 wherein said mesenchymal stem cells are human mesenchymal stem cells.

5. The method of claim 1 wherein said mesenchymal stem cells are from a single donor.

Assignments (8)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0917 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 072297/0753 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 10, 2018
From: MESOBLAST INTERNATIONAL SARL
To: NQP SPV II, L.P., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 046515/0222 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST INTERNATIONAL SARL
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2013
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 031533/0828 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR DOC DATES PREVIOUSLY RECORDED ON REEL 028160 FRAME 0189. ASSIGNOR(S) HEREBY CONFIRMS THE DATES OF EXECUTION OF ASSIGNMENT DOCUMENT. Recorded May 25, 2012
From: DANILKOVITCH, ALLA; CARTER, DIANE; TYRELL, ALICIA; BUBNIC, SIMON; MARCELINO, MICHELLE; MONROY, RODNEY
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 028275/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2012
From: DANILKOVITCH, ALLA; CARTER, DIANE; TYRELL, ALICIA; BUBNIC, SIMON; MARCELINO, MICHELLE; MONROY, RODNEY
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 028160/0189 →